# Special Article

# Use of N95, Surgical, and Cloth Masks to Prevent COVID-19 in Health Care and Community Settings: Living Practice Points From the American College of Physicians (Version 1)

Amir Qaseem, MD, PhD, MHA; Itziar Etxeandia-Ikobaltzeta, PharmD, PhD; Jennifer Yost, RN, PhD; Matthew C. Miller, MD; George M. Abraham, MD, MPH; Adam J. Obley, MD; Mary Ann Forciea, MD; Janet A. Jokela, MD, MPH; and Linda L. Humphrey, MD, MPH; for the Scientific Medical Policy Committee of the American College of Physicians\*

## **KEY QUESTION 1**

What is the effectiveness of N95 respirators versus surgical masks versus cloth masks for the prevention of coronavirus disease 2019 (COVID-19) in addition to standard precautions (gloves + handwashing) in community settings?

## **KEY QUESTION 2**

What is the effectiveness of N95 respirators versus surgical masks versus cloth masks for the prevention of COVID-19 in addition to standard precautions (gowns + gloves + handwashing) in health care settings?

## **KEY QUESTION 3**

What is the effectiveness for reuse or extended use of N95 respirators for prevention of COVID-19?

## BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads among persons in close proximity through droplets, although evidence is still emerging regarding potential airborne transmission. Reducing transmission of SARS-CoV-2 infection in health care and community settings is a major priority, especially in the absence of an effective vaccine or treatment. The use of respiratory personal protective equipment (PPE) may decrease the risk for respiratory infection, although controversy exists around the appropriate types of masks and the situations in which they should be used in community and health care settings for the prevention of SARS-CoV-2 infection. The following practice points (Table 1) are intended for clinicians, patients, and the public. Data on SARS-CoV-2 are limited. These practice points are based on the best available evidence on the effectiveness of N95 respirators, surgical masks, and cloth masks in reducing transmission of infection with SARS-CoV-1, Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza-like or other respiratory viruses in community and health care settings. Evidence about reuse or extended use of N95 respirators in health care settings was also considered.

The American College of Physicians (ACP) based these practice points on a rapid, living systematic evidence review funded by the Agency for Healthcare Research and Quality (1, 2). See the **Appendix** (available at Annals.org) for methods used to develop the practice points. This version of the practice points, based on an evidence review completed on 14 April 2020 with surveillance through 2 June 2020, was approved by the ACP's Executive Committee of Board of Regents on behalf of the Board of Regents on 18 May 2020, and submitted to Annals of Internal Medicine on 13 May 2020. Ongoing surveillance of the literature is planned for 1 year from the initial search date, and the living practice points will be updated alongside the evidence review.

### RATIONALE

What is the effectiveness of N95 respirators, surgical masks, and cloth masks for the prevention of COVID-19 in addition to standard precautions (gloves + handwashing) in community settings?

The goal of using N95 respirators, surgical masks, or cloth masks is to prevent transmission of SARS-CoV-2 infection from asymptomatic or symptomatic infected persons to uninfected persons (source control). Currently, no direct evidence exists for the effectiveness or comparative effectiveness of various types of respirators or masks for preventing SARS-CoV-2 infection in community settings. Low-certainty evidence showed that mask use may reduce the risk for SARS-CoV-1 infection compared with no mask use in the community, but a major limitation of the studies is that they did not specify mask type. Low-certainty indirect evidence also found that

+ Author (participated in discussion and voting).

§ Nonphysician public representative.

This article was published at Annals.org on 18 June 2020.

<sup>\*</sup> This paper, written by Amir Qaseem, MD, PhD, MHA; Itziar Etxeandia-Ikobaltzeta, PharmD, PhD; Jennifer Yost, RN, PhD; Matthew C. Miller, MD; George M. Abraham, MD, MPH; Adam J. Obley, MD; Mary Ann Forciea, MD; Janet A. Jokela, MD, MPH; and Linda L. Humphrey, MD, MPH, was developed for the Scientific Medical Policy Committee of the American College of Physicians. Individuals who served on the Scientific Medical Policy Committee at the time of its approval were Linda L. Humphrey, MD, MPH (Chair)†; Robert M. Centor, MD (Vice Chair)†; Elie Akl, MD, MPH, PhD‡; Rebecca Andrews, MS, MD†; Thomas A. Bledsoe, MD†; Mary Ann Forciea, MD†; Ray Haeme†§; Janet A. Jokela, MD, MPH†; Devan L. Kansagara, MD, MCR†; Maura Marcucci, MD, MSc†; Matthew C. Miller, MD†; and Adam Jacob Obley, MD†. Approved by the ACP Board of Regents on 18 May 2020.

<sup>‡</sup> Nonauthor contributor (participated in discussion but excluded from voting).

Update Alerts: The authors have specified in the Background section and the Appendix (available at Annals.org) the interval and stop date for updates to this Practice Points article. As Annals receives updates, they will appear in the Comments section of the article on Annals.org. Reader inquiries about updates that are not available at approximately the specified intervals should be submitted as Comments to the article.

#### 📣 Table 1. Practice Points

Regardless of the use of respiratory PPE, other procedures to reduce the transmission of SARS-CoV-2 infection should be followed, including maintaining physical distance, self-isolation, quarantine, frequent hand hygiene (using soap and water or alcohol-based hand rub), covering coughs and sneezes by using a bent elbow or paper tissue, refraining from touching the face, and frequent disinfection of frequently touched surfaces (3, 4). Table 2 presents clinical considerations, Table 3 summarizes information on the appropriate use and disposal of respiratory PPE, and Table 4 and the Figure summarize the current evidence.

#### Use of N95 Respirators, Surgical Masks, and Cloth Masks in Community Settings

- ACP discourages the use of N95 respirators by asymptomatic or symptomatic persons in community settings to reduce the risk for SARS-CoV-2 infection in the absence of any demonstrated benefit.
- The decision to use surgical masks or cloth masks to reduce the risk for transmission of SARS-CoV-2 infection among asymptomatic or symptomatic persons in community settings should follow community and statewide public health guidelines for mask use, which should take into account such factors as epidemiologic data (e.g., reproduction rate, daily case counts, hospitalizations, deaths) and local demographics (e.g., high-risk populations).
- Potential harms associated with mask use include self-contamination, breathing difficulties, and a false sense of security that could potentially detract from taking other precautions, such as physical distancing.

#### Use of N95 Respirators, Surgical Masks, and Cloth Masks in Health Care Settings

- All health care personnel in close contact\* with patients suspected or known to have COVID-19 should use N95 respirators in health care settings to reduce the risk for acquiring SARS-CoV-2 infection.
- All patients with suspected or known COVID-19 should wear surgical masks in health care settings.
- All health care personnel, patients, and visitors who are not in close contact with patients with suspected or known COVID-19 should use surgical masks in a health care setting to reduce the risk for transmission of SARS-CoV-2 infection.
- Health care personnel should not use cloth masks in health care settings to reduce the risk for transmission of SARS-CoV-2 infection. Cloth masks are not considered PPE in health care settings, given the lack of evidence of their effectiveness against transmission of SARS-CoV-2 virus.

#### **Reuse or Extended Use of N95 Respirators in Health Care Settings**

No evidence is available on the effectiveness of reuse or extended use of N95 respirators in health care settings.

COVID-19 = coronavirus disease 2019; PPE = personal protective equipment; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. \* Close contact refers to being within 6 feet of a patient with COVID-19 or having direct contact with infectious secretions of a patient with

\* Close contact refers to being within 6 feet of a patient with COVID-19 or having direct contact with infectious secretions of a patient with COVID-19 (5).

N95 respirators may not reduce the risk for noncoronavirus respiratory infections compared with surgical masks or no masks, and moderate-certainty indirect evidence showed that surgical masks probably do not reduce the risk compared with no masks. For surgical masks, there was moderate-certainty evidence of nonserious harms, such as discomfort and difficulty in breathing, compared with no mask use, and low-certainty evidence showed that N95 respirators may not increase discomfort compared with surgical masks. The review identified no eligible studies on the use of cloth masks in community settings.

N95 respirators should not be used in a community setting, given the absence of demonstrated benefit, the possible harm with improper use (that is, the requirement for fit testing), and the global shortage of N95 respirators. Unlike N95 respirators, surgical masks and cloth masks do not require special fitting, making their use more practical if individual fitting is infeasible. Persons should seek guidance from the local community and statewide public health guidelines for mask use in light of the absence of evidence in the community setting to reduce the risk for transmission of SARS-CoV-2 infection. Factors to consider include exposure context (number of people, whether indoors or outdoors, ventilation), epidemiologic data (such as reproduction rate, daily case counts, hospitalizations, and deaths), and local demographics (such as high-risk populations). Individual values and preferences should be taken into account when deciding on the type of mask to use (surgical or cloth mask), because the benefits and harms for surgical versus cloth masks are finely balanced. The use of cloth masks in community settings


has been encouraged by the Centers for Disease Control and Prevention (CDC) (4). The World Health Organization (WHO) recommends a risk-based approach for decision makers when recommending use of nonmedical masks, such as cloth masks, in the community setting (6). The WHO notes potential risks associated with mask use, including self-contamination (via improper handling of masks), breathing difficulties, and a false sense of security that could potentially detract from taking other precautions, such as physical distancing (6). Regardless of mask type, clinicians and public health officials should educate the general public about appropriate mask use (**Table 3**).

Persons at highest risk for SARS-CoV-2 infection are those who are in close contact with persons who have COVID-19 (7, 8). When in close contact with others, persons experiencing symptoms and those in contact with them should wear a surgical mask or cloth mask. A person who interacts with many people (such as flight attendants, restaurant servers, grocery store workers, cab drivers, and others) may benefit from wearing a surgical or cloth mask. The use of masks is not necessary when at home, unless a household member has COVID-19.

What is the effectiveness of N95 respirators, surgical masks, and cloth masks for the prevention of COVID-19 in addition to standard precautions (gowns + gloves + handwashing) in health care settings?

The goal of using respiratory PPE is to reduce exposure and prevent SARS-CoV-2 transmission between health care personnel and patients. Currently, direct evidence on the effectiveness or comparative effectiveness of N95 respirators and surgical masks for prevent-

Figure. Evidence description.



Evidence search and assessment conducted by the Pacific Northwest Evidence-based Practice Center and funded by the Agency for Healthcare Research and Quality (2). Current search for evidence, completed on 14 April 2020 and updated through 2 June 2020, aimed to identify RCTs and OBSs on the use of N95 respirators, surgical masks, and cloth masks to prevent SARS-CoV-2 infection and coronaviruses (SARS-CoV-1, MERS-CoV) infections and RCTs of N95 respirators, surgical masks, and cloth masks to prevent influenza-like (influenza or other respiratory viruses) infections, as well as all studies on the reuse/extended use of N95 respirators. MERS-CoV = Middle East respiratory syndrome coronavirus; OBS = observational study; PCP = primary care physician; PPE = personal protective equipment; RCT = randomized controlled trial; SARS-CoV-2 = severe acute respiratory syndrome 2. \* Different types of respiratory PPE intervention were generally used in addition to additional PPE required for droplet precautions (e.g., gowns, gloves) and hand hygiene in health care settings.

ing SARS-CoV-2 infection in health care settings is insufficient. Given the limited direct evidence, our practice points are based on indirect evidence from studies of SARS-CoV-1, MERS-CoV, influenza or influenza-like infections, and other respiratory infections.

Low-certainty evidence showed that mask use and consistent mask use may reduce the risk for SARS-

### 🕑 Table 2. Clinical Considerations

- SARS-CoV-2 is thought to be transmitted between people through close contact, as droplet transmission.
- SARS-CoV-2 may be transmitted during aerosolized procedures performed in health care settings because there is a higher risk for infection.
- In the evidence reviewed, N95 respirators, surgical masks, and cloth masks were generally used in addition to other PPE required for droplet precautions (e.g., gowns, gloves) and hand hygiene in health care settings.
- In the evidence reviewed, the comparative effectiveness of cloth masks was determined for cloth masks of ≥12 layers, thus concern exists about the applicability of this evidence to commonly used cloth masks.
- In the evidence reviewed, adherence to the use of masks was identified as a possible explanation for the difference or no difference shown in the results.

PPE = personal protective equipment; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

# *Table 3.* Appropriate Use and Disposal of N95 Respirators, Surgical Masks, and Cloth Masks

Appropriate use and disposal of all types of respirators and masks in community and health care settings are crucial to reduce the transmission of SARS-CoV-2 infection. The CDC and WHO recommend the following (6, 12, 13):

- Persons should clean their hands with soap and water or alcohol-based rub before putting on a mask.
- Masks should be properly fitted and should cover the mouth and nose, with no gaps between face and mask.
- All masks should be extended under the chin. Persons should avoid touching the mask and their face, and should especially avoid touching their face when wearing the mask, as well as putting it on and taking it off.
- When taking a mask off, it should be removed from behind without ever touching the front of the respirator/mask.
- Once the mask is removed, hands again should be cleaned with soap and water or alcohol-based rub.
- If using an N95 respirator with a nosepiece, it should be fitted to the nose with both hands, not bent or tented. The straps for an N95 respirator, or ties for a surgical mask, should be placed on the crown of the head (top tie) and base of the neck (bottom tie); for other masks, the loops should be hooked appropriately behind the ears.
- When a cloth mask is used, the following features should be considered: the number of layers of fabric, the breathability of the material used, water repellence/hydrophobic qualities, the shape of the mask, and the fit of the mask.

CDC = Centers for Disease Control and Prevention; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WHO = World Health Organization.

## Table 4. Evidence Summary: What Information Does the Evidence Provide?

N95 Respirators vs. Surgical Masks vs. Cloth Masks in Community Settings

Outcome/Comparison	Study Design (Patients, <i>n</i> )	Evidence†	Certainty of Evidence
Risk for SARS-CoV-2 infection	(ratents, ii)		
No studies			
Dial for companying informations (CADC CoV 4 CADC 4 MED	15 C-10		
Risk for coronavirus infections (SARS-CoV-1, SARS-1, MER Masks (type not specified) vs. no	3 OBSs (2857)	Mask use may reduce the risk for SARS-1 infection	Low
masks	( )	compared with not using masks (26-28).	
Risk for noncoronavirus respiratory infections (influenza-li			
N95 respirators or equivalent vs. surgical masks	1 RCT (290)	N95 respirators may not reduce the risk for influenza-like illness and laboratory confirmed viral respiratory illness compared with surgical masks (22).	Low
N95 respirators or equivalent vs. no masks	1 RCT (290)	N95 respirators may not reduce the risk for laboratory confirmed viral respiratory illness compared with no mask use (22).	Low
Surgical masks vs. no masks	12 RCTs (16 761)	Surgical masks probably do not reduce the risk for clinical respiratory illness (16, 21, 23), influenza-like illness (14, 15, 17-25), laboratory-confirmed viral illness (16, 17, 22, 23), and laboratory-confirmed influenza infection (14, 15, 19-21, 24, 25) compared with no mask use.	Moderate
Evidence for Potential Harms*			
Outcome/Comparison	Study Design (Patients, <i>n</i> )	Evidence†	Certainty of Evidence
N95 respirators or equivalent vs.	1 RCT (290)	N95 respirators or equivalent may not increase the	Low
surgical masks Surgical masks vs. no masks	3 RCTs (8363)	discomfort compared with surgical mask use (22). No adverse events reported with surgical masks (20). Surgical masks probably increase discomfort (16, 18), breathing difficulty (16), and	Moderate
		feeling hot (16) compared with no mask use.	
	N95 Respirators vs. Surgical	Masks vs. Cloth Masks in Health Care Settings	
Vevidence for Potential Benefits*	N95 Respirators vs. Surgical		
Evidence for Potential Benefits*	Study Design		Certainty of Evidence
V		Masks vs. Cloth Masks in Health Care Settings	Certainty of Evidence
<u>V</u>	Study Design	Masks vs. Cloth Masks in Health Care Settings  Evidence†  The evidence is very uncertain about the effectiveness of N95 respirators on the risk for	Certainty of Evidence
Outcome/Comparison Risk for SARS-CoV-2 infection	Study Design (Patients, n)	Masks vs. Cloth Masks in Health Care Settings Evidence† The evidence is very uncertain about the	
Outcome/Comparison Risk for SARS-CoV-2 infection N95 respirators vs. no masks Consistent mask use (non-N95) vs.	Study Design (Patients, n) 1 OBS (493)	Masks vs. Cloth Masks in Health Care Settings         Evidence†         The evidence is very uncertain about the effectiveness of N95 respirators on the risk for SARS-CoV-2 infection (50).         The evidence is very uncertain about the effectiveness of consistent non-N95 respirator use on the risk for SARS-CoV-2 infection compared with inconsistent use (39).         N95 respirators may reduce the risk for SARS-CoV-1 infection compared with surgical masks (36, 37,	Insufficient
Outcome/Comparison Risk for SARS-CoV-2 infection N95 respirators vs. no masks Consistent mask use (non-N95) vs. inconsistent mask use (non-N95) Risk for coronavirus infections (SARS-CoV-1, MERS-CoV) N95 respirators or equivalent masks	Study Design (Patients, n)           1 OBS (493)           1 OBS (37)	Masks vs. Cloth Masks in Health Care Settings         Evidence†         The evidence is very uncertain about the effectiveness of N95 respirators on the risk for SARS-CoV-2 infection (50).         The evidence is very uncertain about the effectiveness of consistent non-N95 respirator use on the risk for SARS-CoV-2 infection compared with inconsistent use (39).         N95 respirators may reduce the risk for SARS-CoV-1 infection compared with surgical masks (36, 37, 41, 42, 47).         The evidence is very uncertain about the effectiveness of N95 respirators or surgical masks (compared with cloth masks (c12 layers, 12-16 layers, ≥16 layers) on the risk for SARS-CoV-1	Insufficient
Outcome/Comparison Risk for SARS-CoV-2 infection N95 respirators vs. no masks Consistent mask use (non-N95) vs. inconsistent mask use (non-N95) Risk for coronavirus infections (SARS-CoV-1, MERS-CoV) N95 respirators or equivalent masks vs. surgical masks N95 respirators or surgical masks vs.	Study Design (Patients, n)           1 OBS (493)           1 OBS (37)           5 OBSs (1208)	Masks vs. Cloth Masks in Health Care Settings         Evidence†         The evidence is very uncertain about the effectiveness of N95 respirators on the risk for SARS-CoV-2 infection (50).         The evidence is very uncertain about the effectiveness of consistent non-N95 respirator use on the risk for SARS-CoV-2 infection compared with inconsistent use (39).         N95 respirators may reduce the risk for SARS-CoV-1 infection compared with surgical masks (36, 37, 41, 42, 47).         The evidence is very uncertain about the effectiveness of N95 respirators or surgical masks compared with cloth masks (<12 layers, 12-16 layers, >16 layers) on the risk for SARS-CoV-1 infection (41, 43, 52).         The evidence is very uncertain about the effectiveness of N95 respirators or surgical masks	Insufficient Insufficient Low
Outcome/Comparison Risk for SARS-CoV-2 infection N95 respirators vs. no masks Consistent mask use (non-N95) vs. inconsistent mask use (non-N95) Risk for coronavirus infections (SARS-CoV-1, MERS-CoV) N95 respirators or equivalent masks vs. surgical masks N95 respirators or surgical masks vs. cloth masks N95 respirators or surgical masks vs.	Study Design (Patients, n)           1 OBS (493)           1 OBS (37)           5 OBSs (1208)           3 OBSs (1207)	Masks vs. Cloth Masks in Health Care Settings         Evidence†         The evidence is very uncertain about the effectiveness of N95 respirators on the risk for SARS-CoV-2 infection (50).         The evidence is very uncertain about the effectiveness of consistent non-N95 respirator use on the risk for SARS-CoV-2 infection compared with inconsistent use (39).         N95 respirators may reduce the risk for SARS-CoV-1 infection compared with surgical masks (36, 37, 41, 42, 47).         The evidence is very uncertain about the effectiveness of N95 respirators or surgical masks compared with cloth masks (121 ayers, 12-16 layers, ≥16 layers) on the risk for SARS-CoV-1 infection (41, 43, 52).         The evidence is very uncertain about the	Insufficient Insufficient Low Insufficient

Continued on following page

#### Table 4-Continued

N95 Respirators vs. Surgical Masks vs. Cloth Masks in Health Care Settings

Outcome/Comparison	Study Design (Patients, <i>n</i> )	Evidence†	Certainty of Evidence
Cloth masks vs. no masks	3 OBSs (1177)	The evidence is very uncertain about the effectiveness of cloth masks (defined as cotton mask, double 12-layer cotton [surgical] mask, or ≥12-layer mask) compared with no masks on the risk for SARS-CoV-1 infection (41, 46, 52).	Insufficient
Masks (type not specified) vs. no masks	5 OBSs (1167)	Mask use may reduce the risk for SARS-CoV-1 infection compared with no masks (43, 45, 48, 51, 52).	Low
Consistent mask use (type not specified) vs. inconsistent use	4 OBSs (626)	More consistent mask use may reduce the risk for SARS-CoV-1 and MERS-CoV infection compared with nonconsistent mask use (35, 40, 42, 45).	Low
Risk for noncoronavirus respiratory infections (ii	nfluenza-like or other viral respiratory)		
N95 respirators vs. surgical masks in higher-risk settings	3 RCTs (3532)	N95 respirators probably do not reduce the risk for clinical respiratory illness, influenza-like illness, and laboratory-confirmed viral infections compared with surgical masks in high-risk settings (31-33).	Moderate
N95 respirators vs. surgical masks in lower-risk settings	1 RCT (2862)	N95 respirators probably do not reduce the risk for clinical respiratory illness, influenza-like illness, laboratory-confirmed viral respiratory illness, and laboratory-confirmed influenza compared with surgical masks in low-risk settings (34).	Moderate
Surgical masks vs. cloth masks in higher-risk settings	1 RCT (1868)	Surgical masks may reduce the risk for clinical respiratory illness, laboratory-confirmed viral infections, and influenza-like illness compared	Low
		with cloth masks in high-risk settings (30).	
Evidence for Potential Harms*		with cloth masks in high-risk settings (30).	
Evidence for Potential Harms*	Study Design (Patients, n)	with cloth masks in high-risk settings (30). Evidence†	Certainty of Evidence
			Certainty of Evidence
Dutcome/Comparison N95 respirators or equivalent mask vs.	(Patients, n)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical	Certainty of Evidence Low Moderate
Dutcome/Comparison N95 respirators or equivalent mask vs. surgical masks	(Patients, n) 4 RCTs (6394) 1 RCT (1868)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical masks (32, 33). Use of surgical masks probably does not increase adverse events (e.g., discomfort, breathing problems,	Low
Dutcome/Comparison N95 respirators or equivalent mask vs. surgical masks	(Patients, n) 4 RCTs (6394) 1 RCT (1868)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical masks (32, 33). Use of surgical masks probably does not increase adverse events (e.g., discomfort, breathing problems, headache) compared with cloth masks (30).	Low
Outcome/Comparison N95 respirators or equivalent mask vs. surgical masks Surgical masks vs. cloth masks Very Evidence for Potential Benefits*	(Patients, n) 4 RCTs (6394) 1 RCT (1868)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical masks (32, 33). Use of surgical masks probably does not increase adverse events (e.g., discomfort, breathing problems, headache) compared with cloth masks (30).	Low
Dutcome/Comparison N95 respirators or equivalent mask vs. surgical masks Surgical masks vs. cloth masks	(Patients, n) 4 RCTs (6394) 1 RCT (1868)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical masks (32, 33). Use of surgical masks probably does not increase adverse events (e.g., discomfort, breathing problems, headache) compared with cloth masks (30).	Low
Dutcome/Comparison N95 respirators or equivalent mask vs. surgical masks Surgical masks vs. cloth masks  Evidence for Potential Benefits* No studies	(Patients, n) 4 RCTs (6394) 1 RCT (1868)	Evidence† No (serious) adverse events reported with N95 or equivalent respirators in RCTs (31, 34). N95 respirators may increase discomfort, breathing difficulty, and headache compared with surgical masks (32, 33). Use of surgical masks probably does not increase adverse events (e.g., discomfort, breathing problems, headache) compared with cloth masks (30).	Low

• Comparative efficacy and safety of different types of respiratory PPE for preventing SARS-CoV-2 infection in community settings [no evidence].

• Comparative efficacy and safety of different types of respiratory PPE for preventing SARS-CoV-2 infection in health care settings [insufficient evidence].

- Efficacy and safety of the reuse or extended use of N95 respirators [no evidence].
- Safety of all types of respiratory PPE [insufficient evidence].
- An urgent need exists for high-quality trials and observational studies to better understand the benefits and harms of using various types of respiratory PPE and cloth masks, and of mask characteristics (e.g., use of filters), types of filters), in community settings.

CoV = coronavirus; MERS = Middle East respiratory syndrome; OBS = observational study; PPE = personal protective equipment; RCT = randomized controlled trial; SARS = severe acute respiratory syndrome.

\* N95: close facial fit, blocking 95% of 0.3-µm particles. Surgical/medical masks are loose fitting, blocking larger particles and splashes or spatter. Cloth masks are nonmedical, unstandardized face coverings and vary depending on type of cloth, number of layers, and tightness of fit. † Evidence search and assessment conducted by the Pacific Northwest Evidence-based Practice Center and funded by the Agency for Healthcare

Research and Quality (1). See the **Supplement** (available at Annals.org) for data estimates. ‡ Certainty: *insufficient*-confidence is inadequate to accurately assess the net benefit (benefit minus harm) of an intervention or its impact on a health outcome; *low*-confidence in the effect is limited because the true effect may be substantially different from the estimated effect; *moderate*confidence in the effect is moderate because the true effect is likely close to the estimated effect, but there is a sizable possibility that it is substantially different; *high*-confidence that the true effect is close to the estimated effect (53).

## Special Article

CoV-1 infection compared with no mask use and inconsistent mask use in health care settings, but studies did not specify mask type. Low-certainty indirect evidence showed that N95 respirators may reduce the risk for SARS-CoV-1 infection compared with surgical masks or no masks. Indirect evidence from studies reporting on the risk for noncoronavirus respiratory infections showed that N95 respirators probably do not reduce the risk for noncoronavirus respiratory infections compared with surgical masks (moderate certainty) and that surgical masks may reduce the risk for clinical respiratory illness, laboratory-confirmed viral infections, and influenza-like illness compared with cloth masks (low certainty). Indirect evidence was insufficient about the effect of N95 respirators or surgical masks compared with cloth masks, and surgical masks and cloth masks compared with no masks, on the risk for SARS-CoV-1 infection. Low-certainty evidence showed that N95 respirators may increase some nonserious harms, such as discomfort, breathing difficulties, and headache, compared with surgical masks and moderate-certainty indirect evidence that those harms probably do not increase with the use of surgical masks compared with cloth masks.

Uncertainty about airborne transmission of SARS-CoV-2 continues (9). Health care workers are at an increased risk for infection, because they are more likely to be in close contact with patients who are confirmed or suspected to have COVID-19. The CDC does not consider cloth masks as PPE in health care settings, given the lack of evidence of their effectiveness against transmission of SARS-CoV-2 (10).

Health care personnel should not be exposed to patients suspected or known to have COVID-19 without proper PPE. It is essential to strictly follow all other infection prevention and control measures (such as hand hygiene, physical distancing, and others) along with appropriate use of other PPE (such as gowns, gloves, and goggles) in health care settings.

What is the effectiveness for reuse or extended use of N95 respirators for prevention of COVID-19?

Extended use is defined as wearing the same N95 respirator without removal between patient encounters (5). Reuse is defined as using the same N95 respirator for several encounters with patients but removing it after each encounter (5). Currently, no evidence is available about the effectiveness of extended use or reuse of N95 respirators in health care settings. However, on the basis of an assessment of nonclinical outcomes (such as measures of filtration, contamination, and mask failure), a previous review comparing extended use and reuse of N95 respirators is preferable to reuse of N95 respirators because it involves less touching of the respirator, thus less risk for contact transmission (11).

From American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.); American College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.); Penn Medicine, Philadelphia, Pennsylvania (M.C.M., M.A.F.); University of Massachusetts Medical School and Saint Vincent

Hospital, Worcester, Massachusetts (G.M.A.); Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (A.J.O., L.L.H.); and University of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois (J.A.J.).

**Note:** The Practice Points are developed by the Scientific Medical Policy Committee of the American College of Physicians. The Practice Points are "guides" only and may not apply to all patients and all clinical situations. All Practice Points are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.

**Financial Support:** Financial support for the development of the Practice Points comes exclusively from the ACP operating budget.

**Disclosures:** All financial and intellectual disclosures of interest were declared and potential conflicts were discussed and managed. Dr. Akl participated in discussion of the Practice Points but was recused from authorship and voting due to a moderate-level conflict of interest (author of recent relevant systematic review). A record of disclosures of interest and management of conflicts of interest is kept for each Scientific Medical Policy Committee meeting and conference call and can be viewed at https://www.acp online.org/about-acp/who-we-are/leadership/boards-committees -councils/scientific-medical-policy-committee/disclosure-of -interests-and-conflict-of-interest-management-summary-for -scientific-medical-policy. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms .do?msNum=M20-3234.

**Corresponding Author:** Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, aqaseem@acponline.org.

Current author addresses and author contributions are available at Annals.org.

Ann Intern Med. doi:10.7326/M20-3234

### References

1. Chou R, Dana T, Jungbauer R, et al. Masks for Prevention of COVID-19 in Community and Healthcare Settings: A Living Rapid Review. Rapid Evidence Product. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I). AHRQ publication no. 20-EHC016. Agency for Healthcare Research and Quality; June 2020. doi:10.23970/AHRQEPC COVIDMASKS

2. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections including SARS-CoV-2 in health care and community settings. A living and rapid review. Ann Intern Med. [Forthcoming].

3. World Health Organization. Advice on the use of masks in the context of COVID-19. Interim guidance 6 April 2020. Accessed at https://apps.who.int/iris/rest/bitstreams/1274280/retrieve on 29 April 2020.

4. Centers for Disease Control and Prevention. Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. Accessed at www.cdc.gov /coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html on 7 May 2020.

5. Centers for Disease Control and Prevention. Evaluating and testing persons for coronavirus disease 2019 (COVID-19). Accessed at www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html on 8 May 2020.

6. World Health Organization. Advice on the use of masks in the context of COVID-19. Interim guidance 5 June 2020. Accessed at https://apps.who.int/iris/rest/bitstreams/1279750/retrieve on 9 June 2020.

7. World Health Organization. Q&A on coronaviruses (COVID-19). Accessed at www.who.int/emergencies/diseases/novel-coronavirus -2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses on 12 May 2020.

8. Centers for Disease Control and Prevention. Quarantine and isolation. Accessed at www.cdc.gov/coronavirus/2019-ncov/if-you-are -sick/quarantine-isolation.html on 12 May 2020.

9. Lewis D. Is the coronavirus airborne? Experts can't agree. Nature. 2020;580:175. [PMID: 32242113] doi:10.1038/d41586-020-00974-w

10. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in health-care settings. Accessed at www.cdc.gov/coronavirus/2019-ncov/hcp /infection-control-recommendations.html on 7 May 2020.

11. Emergency Care Research Institute. Clinical evidence assessment. Safety of extended use and reuse of N95 respirators. Accessed at https://assets.ecri.org/PDF/COVID-19-Resource-Center/COVID -19-Clinical-Care/COVID-ECRI-N95-Respirators-updated-4.pdf on 16

April 2020. 12. Centers for Disease Control and Prevention. Using personal pro-

tective equipment (PPE). Accessed at www.cdc.gov/coronavirus /2019-ncov/hcp/using-ppe.html on 29 April 2020.

13. World Health Organization. Coronavirus disease (COVID-19) advice for the public: when and how to use masks. Accessed at www.who.int/emergencies/diseases/novel-coronavirus-2019 /advice-for-public/when-and-how-to-use-masks on 8 May 2020.

14. Aiello AE, Murray GF, Perez V, et al. Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. J Infect Dis. 2010;201:491-8. [PMID: 20088690] doi:10.1086/650396

15. Aiello AE, Perez V, Coulborn RM, et al. Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. PLoS One. 2012;7:e29744. [PMID: 22295066] doi:10.1371 /journal.pone.0029744

16. Alfelali M, Haworth EA, Barasheed O, et al. Facemask versus no facemask in preventing viral respiratory infections during Hajj: a cluster randomised open label trial. Accessed at https://papers.ssrn.com /sol3/papers.cfm?abstract\_id=3349234 on 12 June 2020.

17. Barasheed O, Almasri N, Badahdah AM, et al; Hajj Research Team. Pilot randomised controlled trial to test effectiveness of facemasks in preventing influenza-like illness transmission among Australian Hajj pilgrims in 2011. Infect Disord Drug Targets. 2014;14:110-6. [PMID: 25336079]

18. Canini L, Andréoletti L, Ferrari P, et al. Surgical mask to prevent influenza transmission in households: a cluster randomized trial. PLoS One. 2010;5:e13998. [PMID: 21103330] doi:10.1371/journal .pone.0013998

19. Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med. 2009;151:437-46. [PMID: 19652172] 20. Cowling BJ, Fung RO, Cheng CK, et al. Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS One. 2008;3:e2101. [PMID: 18461182] doi:10.1371/journal.pone.0002101

21. Larson EL, Ferng YH, Wong-McLoughlin J, et al. Impact of nonpharmaceutical interventions on URIs and influenza in crowded, urban households. Public Health Rep. 2010 Mar-Apr;125:178-91. [PMID: 20297744]

22. MacIntyre CR, Cauchemez S, Dwyer DE, et al. Face mask use and control of respiratory virus transmission in households. Emerg Infect Dis. 2009;15:233-41. [PMID: 19193267]

23. MacIntyre CR, Zhang Y, Chughtai AA, et al. Cluster randomised controlled trial to examine medical mask use as source control for people with respiratory illness. BMJ Open. 2016;6:e012330. [PMID: 28039289] doi:10.1136/bmjopen-2016-012330

24. Simmerman JM, Suntarattiwong P, Levy J, et al. Findings from a household randomized controlled trial of hand washing and face masks to reduce influenza transmission in Bangkok, Thailand. Influenza Other Respir Viruses. 2011;5:256-67. [PMID: 21651736] doi:10.1111/j.1750-2659.2011.00205.x

25. Suess T, Remschmidt C, Schink SB, et al. The role of facemasks and hand hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009-2011. BMC Infect Dis. 2012;12:26. [PMID: 22280120] doi:10 .1186/1471-2334-12-26

26. Lau JT, Lau M, Kim JH, et al. Probable secondary infections in households of SARS patients in Hong Kong. Emerg Infect Dis. 2004; 10:235-43. [PMID: 15030689]

27. Tuan PA, Horby P, Dinh PN, et al; WHO SARS Investigation Team in Vietnam. SARS transmission in Vietnam outside of the health-care setting. Epidemiol Infect. 2007;135:392-401. [PMID: 16870029]

28. Wu J, Xu F, Zhou W, et al. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerg Infect Dis. 2004;10:210-6. [PMID: 15030685]

29. Chughtai AA, Seale H, Dung TC, et al. Compliance with the use of medical and cloth masks among healthcare workers in vietnam. Ann Occup Hyg. 2016;60:619-30. [PMID: 26980847] doi:10.1093 /annhyg/mew008

30. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015;5:e006577. [PMID: 25903751] doi:10.1136 /bmjopen-2014-006577

31. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA. 2009;302:1865-71. [PMID: 19797474] doi:10.1001 /jama.2009.1466

32. MacIntyre CR, Wang Q, Cauchemez S, et al. A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. Influenza Other Respir Viruses. 2011;5:170-9. [PMID: 21477136] doi:10.1111/j.1750-2659.2011.00198.x

33. MacIntyre CR, Wang Q, Seale H, et al. A randomized clinical trial of three options for N95 respirators and medical masks in health workers. Am J Respir Crit Care Med. 2013;187:960-6. [PMID: 23413265] doi:10.1164/rccm.201207-1164OC

34. Radonovich LJ Jr, Simberkoff MS, Bessesen MT, et al; ResPECT investigators. N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial. JAMA. 2019;322:824-833. [PMID: 31479137] doi:10.1001/jama.2019 .11645

35. Alraddadi BM, Al-Salmi HS, Jacobs-Slifka K, et al. Risk factors for Middle East respiratory syndrome coronavirus infection among healthcare personnel. Emerg Infect Dis. 2016;22:1915-1920. [PMID: 27767011] doi:10.3201/eid2211.160920

36. Scales DC, Green K, Chan AK, et al. Illness in intensive care staff after brief exposure to severe acute respiratory syndrome. Emerg Infect Dis. 2003;9:1205-10. [PMID: 14609453]

37. Caputo KM, Byrick R, Chapman MG, et al. Intubation of SARS patients: infection and perspectives of healthcare workers. Can J Anaesth. 2006;53:122-9. [PMID: 16434750]

38. Chen WQ, Ling WH, Lu CY, et al. Which preventive measures might protect health care workers from SARS? BMC Public Health. 2009;9:81. [PMID: 19284644] doi:10.1186/1471-2458-9-81

39. Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:472-476. [PMID: 32298249] doi:10 .15585/mmwr.mm6915e5

40. Lau JT, Fung KS, Wong TW, et al. SARS transmission among hospital workers in Hong Kong. Emerg Infect Dis. 2004;10:280-6. [PMID: 15030698]

## Special Article

41. Liu W, Tang F, Fang L-Q, et al. Risk factors for SARS infection among hospital healthcare workers in Beijing: a case control study. Trop Med Int Health. 2009;14(Suppl 1):52-9.

42. Loeb M, McGeer A, Henry B, et al. SARS among critical care nurses, Toronto. Emerg Infect Dis. 2004;10:251-5. [PMID: 15030692] 43. Ma HJ, Wang HW, Fang LQ, et al. [A case-control study on the risk factors of severe acute respiratory syndromes among health care workers]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:741-4. [PMID: 15555351]

44. Nishiura H, Kuratsuji T, Quy T, et al. Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam. Am J Trop Med Hyg. 2005;73:17-25. [PMID: 16014825]

45. Nishiyama A, Wakasugi N, Kirikae T, et al. Risk factors for SARS infection within hospitals in Hanoi, Vietnam. Jpn J Infect Dis. 2008; 61:388-90. [PMID: 18806349]

46. Pei LY, Gao ZC, Yang Z, et al. Investigation of the influencing factors on severe acute respiratory syndrome among health care workers. Beijing Da Xue Xue Bao Yi Xue Ban. 2006;38:271-5. [PMID: 16778970]

47. Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010;5:e10717. [PMID: 20502660] doi:10.1371/journal.pone.0010717

48. Seto WH, Tsang D, Yung RW, et al; Advisors of Expert SARS group of Hospital Authority. Effectiveness of precautions against

droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet. 2003;361:1519-20. [PMID: 12737864]

49. Teleman MD, Boudville IC, Heng BH, et al. Factors associated with transmission of severe acute respiratory syndrome among health-care workers in Singapore. Epidemiol Infect. 2004;132:797-803. [PMID: 15473141]

50. Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use [Letter]. J Hosp Infect. 2020;105:104-105. [PMID: 32142885] doi:10.1016/j.jhin.2020.02.021

51. Wilder-Smith A, Teleman MD, Heng BH, et al. Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. Emerg Infect Dis. 2005;11:1142-5. [PMID: 16022801]

52. Yin WW, Gao LD, Lin WS, et al. [Effectiveness of personal protective measures in prevention of nosocomial transmission of severe acute respiratory syndrome]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:18-22. [PMID: 15061941]

53. Qaseem A, Kansagara D, Lin JS, et al; Clinical Guidelines Committee of the American College of Physicians. The development of clinical guidelines and guidance statements by the Clinical Guidelines Committee of the American College of Physicians: update of methods. Ann Intern Med. 2019;170:863-870. [PMID: 31181568] doi:10.7326/M18-3290 **Current Author Addresses:** Dr. Qaseem: American College of Physicians, 190 N Independence Mall West, Philadelphia, PA 19106.

Dr. Etxeandia-Ikobaltzeta: 1, Santa Margarita Hospital Street, Ground Floor 2, Office 1, Room 2, 20303 Irun, Gipuzkoa, Spain.

Dr. Yost: 800 Lancaster Avenue, Villanova, PA 19085.

Dr. Miller: Penn Medicine Radnor, 250 King of Prussia Road, Radnor, PA 19087.

Dr. Abraham: 123 Summer Street, Suite 370, North Worcester, MA 01608.

Dr. Obley: 3030 Southwest Moody, Suite 250, Portland, OR 97201.

Dr. Forciea: 3615 Chestnut Street, Philadelphia, PA 19104.

Dr. Jokela: Carle Forum, 611 West Park, Urbana, IL 61801.

Dr. Humphrey: 12310 Northwest Tualatin Avenue, Portland, OR 97229.

Author Contributions: Conception and design: A. Qaseem, I. Etxeandia-Ikobaltzeta, J. Yost, J.A. Jokela, A.J. Obley, M. Marcucci.

Analysis and interpretation of the data: A. Qaseem, I. Etxeandia-Ikobaltzeta, J. Yost, M.C. Miller, A.J. Obley, M.A. Forciea, J.A. Jokela, L.L. Humphrey, E.A. Akl.

Drafting of the article: A. Qaseem, I. Etxeandia-Ikobaltzeta, J. Yost, G.M. Abraham, J.A. Jokela.

Critical revision for important intellectual content: A. Qaseem, I. Etxeandia-Ikobaltzeta, J. Yost, M.C. Miller, A.J. Obley, J.A. Jokela, L.L. Humphrey, E.A. Akl, R. Andrews, R.A. Haeme, D. Kansagara, M. Marcucci.

Final approval of the article: A. Qaseem, I. Etxeandia-Ikobaltzeta, J. Yost, M.C. Miller, G.M. Abraham, A.J. Obley, Mary Ann Forciea, J.A. Jokela, L.L. Humphrey, E.A. Akl, R. Andrews, T.A. Bledsoe, R.M. Centor, R.A. Haeme, D. Kansagara, M. Marcucci.

Statistical expertise: A. Qaseem, J. Yost.

Administrative, technical, or logistic support: A. Qaseem, J. Yost.

Collection and assembly of data: I. Etxeandia-Ikobaltzeta, J. Yost.

## **APPENDIX: PRACTICE POINTS DEVELOPMENT PROCESS**

The Scientific Medical Policy Committee (SMPC), in collaboration with staff from ACP's Department of Clinical Policy, developed these practice points on the basis of a rapid systematic evidence review conducted by the Pacific Northwest Evidence-based Practice Center and funded by the Agency for Healthcare Research and Quality (1, 2). The SMPC comprises 11 internal medicine physicians representing various clinical areas of expertise and 1 public (nonclinician) member, and includes members with expertise in epidemiology, healthy policy, and evidence synthesis. In addition to contributing clinical, scientific, and methodological expertise, Clinical Policy staff provided administrative support and liaised between the SMPC, evidence review funding entity and evidence team, and journal. Clinical Policy staff and the SMPC reviewed and prioritized potential topic suggestions from ACP members, SMPC members, and ACP governance. A committee subgroup, including the chair of the SMPC, worked with staff to draft the key questions and lead the development of the practice points. Clinical Policy staff worked with the subgroup and an independent evidence review team to refine the key questions and determine appropriate evidence synthesis methods for each key question. Via conference calls and e-mail, Clinical Policy staff worked with the committee subgroup to draft the practice points on the basis of the results of the rapid systematic evidence review. The full SMPC reviewed and approved the final practice points. Before journal submission, ACP's Executive Committee of the Board of Regents also reviewed and approved the practice points on behalf of the ACP Board of Regents. The evidence review will be continually updated by the evidence review team. American College of Physicians will update the practice points on the basis of the evidence review by using the same process as the Version 1 (described above).